Obviously, we will know the full details when the trial protocol comes out, but I don't think Clarity even have to demonstrate superiority (which they are so confident of): Non Inferiority is normally good enough for this type of thing!
"The primary objective of the study is to compare the detection rate of sites of prostate cancer recurrence, as determined by number of lesions per patient, between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT)."
CU6 Price at posting:
$6.71 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)